CClinicalTrials.gg
CompletedNCT00732758Vitamin D RCTUpdated Dec 29, 2015Results posted

Defining Vitamin D Insufficiency in School Age Children: A Randomized Placebo Controlled Trial of Vitamin D3

A Phase 1 interventional study of Vitamin D3 1000 IU and Placebo Tablet in Healthy, sponsored by University of Pittsburgh. Completed at 1 site in United States. Open to participants aged 8 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-12-29.

Sponsored by University of Pittsburgh · Phase 1, Interventional, and Diagnostic

Phase
Phase 1
Study type
Interventional
Enrollment
157
Allocation
Randomized
Ages
8 Years to 14 Years
Sex
All
01

Study summary

The study objective is to characterize the threshold levels of serum 25-hydroxyvitamin D for the definition of vitamin D insufficiency in 8-14 year old African American and Caucasian children.

We propose a 6 month randomized placebo controlled trial of vitamin D (vitamin D3 1000 IU/day vs. placebo) initiated during October through March (during fall and winter) in 8 to 14 year old African American and Caucasian children. The results of the trial will help establish the cutoff threshold value of serum 25(OH)D for defining vitamin D insufficiency in preadolescent and adolescent children. Safety of vitamin D supplementation will be assessed by measuring serum calcium at 0, 2 and 6 months and by monitoring for adverse events. Currently recommended adequate intake for vitamin D of 200 IU daily may not meet the body's daily needs for vitamin D. Therefore, it is likely that a higher level of daily vitamin D intake may be needed to meet the body's skeletal and non-skeletal demands for vitamin D. Determining the dietary required intake of vitamin D for the prevention of vitamin D insufficiency during childhood has immense public health potential for addressing health disparities and ensuring better bone health during adulthood. The primary outcome measure will be serum 25(OH)D and parathyroid hormone (PTH). The secondary outcome measures will include: markers of bone formation (serum P1NP) and bone resorption (serum CTX).We will also examine differences in serum 25(OH)D, PTH, and markers of bone turnover in African American vs. Caucasian children.

Read the detailed description

Epidemiologic and clinical data document a high prevalence of vitamin D insufficiency among adults and adolescents in the US. Vitamin D insufficiency during childhood has the potential to impact the acquisition of peak bone mass. Vitamin D insufficiency is also associated with several non-skeletal disorders including cancer (prostate, breast, and colon), diabetes mellitus (type 1 and type 2), and multiple sclerosis. In our pilot study nearly 50% of 6 to 10 year old African American children residing in Pittsburgh, Pennsylvania, were deemed vitamin D insufficient (serum 25-hydroxyvitamin D (25(OH)D): ≤ 20 ng/mL; Rajakumar K, et al. Clinical Pediatrics. 2005;44:683-692). To extend this field further, we are proposing a randomized placebo-controlled trial of vitamin D3 for establishing the serum 25-hydroxyvitamin D (25(OH)D) cutoff threshold levels for defining vitamin D insufficiency during childhood and to document the safety and efficacy of treatment on the vitamin D status of the study cohort. A total of 168 (African American: 84, Caucasian: 84) 8 to 14 year old preadolescent and adolescent children will undergo a randomized-placebo controlled trial (RCT) of vitamin D3 1000 IU daily vs. placebo for 6 months initiated during fall and winter (October through March). Safety of vitamin D supplementation will be assessed by measuring serum calcium at 0, 2 and 6 months and by monitoring for adverse events. We will also examine the differences in serum 25(OH)D, PTH, and markers of bone turnover in African American vs. Caucasian children. The primary outcome measure will be serum 25(OH)D and PTH. The secondary outcome measures will include: markers of bone formation: serum osteocalcin (OC) and bone resorption: serum C-terminal cross-linking telopeptide of type 1 collagen (serum CTX). Additional outcomes will include: dietary intake of vitamin D and calcium, skin color (Fitzpatrick Sunreactive Skin Type and Melanin Index), sun exposure, and body mass index. Vitamin D deficiency will be defined as serum 25-hydroxyvitamin D concentrations \<20 ng/mL. Public health importance of childhood vitamin D insufficiency is linked to the impact of vitamin D status on the acquisition of peak bone mass. Reduced peak bone mass can predispose to premature onset of osteoporosis and increase the risk for osteoporosis related fragility fractures. Achieving and maintaining vitamin D sufficiency during childhood can positively impact the skeletal health of children and reduce their "osteoporosis" burden during adulthood, and modify their risk for the non-skeletal disorders associated with chronic vitamin D insufficiency. Paucity of data regarding threshold levels of serum 25(OH)D associated with vitamin D insufficiency status among school age children and the likelihood that the serum 25(OH)D threshold levels for vitamin D sufficiency could be different among African American and Caucasian children makes it compelling for this issue to be explored. Based on expert opinion and supportive data in the medical literature, we feel that the currently recommended adequate intake for vitamin D for pre- and adolescent children (200 IU daily) is woefully inadequate to meet the daily needs for vitamin D. Therefore, it is likely that a higher level of daily vitamin D intake may be needed to meet the body's skeletal and non-skeletal demands for vitamin D. This study will determine the serum 25(OH)D cutoff for the definition of vitamin D insufficiency and document the safety and efficacy of treatment on vitamin D status.

02

Conditions studied

  • Healthy

Keywords

  • Vitamin D Deficiency
  • Vitamin D Insufficiency
  • Child
  • Adolescent
  • African American
  • Caucasian
  • Definition
  • Preadolescent
03

In context

Lead sponsor

University of Pittsburgh is the lead sponsor of 1,385 studies on the registry; 167 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age: 8-14 years
  • Race: African American or Caucasian
  • Children not taking multivitamins for at least 1 month before enrollment and agree not to start any multivitamin supplements during the 6-month trial period.
  • Children who are on multivitamins can be considered for enrollment only if they are able to and agree to stop their multivitamin tablet for a 1 month washout period prior to enrollment.
  • Absence of chronic diseases that could affect growth or calcium or vitamin D metabolism

Exclusion criteria

Exclusion Criteria:

  • Hepatic or renal disease
  • Metabolic rickets
  • Malabsorptive disorders (Crohn's disease, cystic fibrosis and celiac disease) or cancer
  • Treatment with anticonvulsants or systemic glucocorticoids
05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
157 participants (actual)

Study arms

  • Experimental
    Vitamin D3

    Vitamin D3 1000 IU Tablet

    Dietary Supplement: Vitamin D3 1000 IU

  • Placebo comparator
    Placebo

    Placebo Tablet

    Dietary Supplement: Placebo Tablet

Interventions

  • Dietary supplementVitamin D3 1000 IU

    Vitamin D3 1000 IU Tablet once daily for 6 months

  • Dietary supplementPlacebo Tablet

    Placebo Tablet once daily for 6 months

06

What researchers measure

Primary outcomes

  1. Serum 25-hydroxyvitamin D

    Circulating concentration of 25 hydroxyvitamin D is a biomarker of vitamin D status. Vitamin D deficiency was defined as serum 25-hydroxyvitamin D concentrations \<20 ng/mL.

    Time frame: 6 months

Secondary outcomes

  1. Parathyroid Hormone (PTH) Dietary Data

    Time frame: 6 months

  2. Osteocalcin (OC)

    Marker of bone formation

    Time frame: 6 months

  3. Collagen Type 1 Cross-linked C-telopeptide (CTx)

    Collagen type 1 cross-linked C-telopeptide (CTx) is a marker of bone resorption.

    Time frame: 6 months

07

Results

Posted Oct 22, 2015
Limitations and caveats
No limitations.

Participant flow

We enrolled healthy 8- to 14-year-old children from October through March of 2008 through 2011.

Participant flow — Overall Study
MilestoneVitamin D3 GroupPlacebo Group
Started7879
Completed7063
Not completed816
Withdrew: Lost to follow-up816

Outcome measures

PrimarySerum 25-hydroxyvitamin D

Circulating concentration of 25 hydroxyvitamin D is a biomarker of vitamin D status. Vitamin D deficiency was defined as serum 25-hydroxyvitamin D concentrations \<20 ng/mL.

Time frame:
6 months
Reported as:
Mean · ng/mL
Serum 25-hydroxyvitamin D
ng/mLVitamin D3 GroupPlacebo Group
Serum 25-hydroxyvitamin D26.7 ± 7.622.4 ± 7.3
Statistical analysis
  • Vitamin D3 Group vs Placebo Group · ANCOVA · p = 0.003adjusting for baseline 25(OH)D, race, BMI, diet vitamin D, gender, pubertal status, and sunlight exposure.
SecondaryParathyroid Hormone (PTH) Dietary Data
Time frame:
6 months
Reported as:
Mean · pg/mL
Parathyroid Hormone (PTH) Dietary Data
pg/mLVitamin D3 GroupPlacebo Group
Parathyroid Hormone (PTH) Dietary Data35.5 ± 16.333.5 ± 17.0
Statistical analysis
  • Vitamin D3 Group vs Placebo Group · t-test, 2 sided · p = 0.51unadjusted p-values
SecondaryOsteocalcin (OC)

Marker of bone formation

Time frame:
6 months
Reported as:
Mean · ng/mL
Osteocalcin (OC)
ng/mLVitamin D3 GroupPlacebo Group
Osteocalcin (OC)101.1 ± 48.3104.8 ± 48.7
Statistical analysis
  • Vitamin D3 Group vs Placebo Group · t-test, 2 sided · p = 0.66
SecondaryCollagen Type 1 Cross-linked C-telopeptide (CTx)

Collagen type 1 cross-linked C-telopeptide (CTx) is a marker of bone resorption.

Time frame:
6 months
Reported as:
Mean · ng/mL
Collagen Type 1 Cross-linked C-telopeptide (CTx)
ng/mLVitamin D3 GroupPlacebo Group
Collagen Type 1 Cross-linked C-telopeptide (CTx)1.4 ± 0.91.6 ± 0.9
Statistical analysis
  • Vitamin D3 Group vs Placebo Group · t-test, 2 sided · p = 0.35

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vitamin D3 Group—0/78 (0%)0/78 (0%)
Placebo Group—0/79 (0%)0/79 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Vitamin D3 GroupPlacebo GroupTotal
Mean11.2 ± 1.911.4 ± 2.011.3 ± 1.95
Sex: Female, Male
Sex: Female, Male(Participants)Vitamin D3 GroupPlacebo GroupTotal
Female453479
Male334578
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Vitamin D3 GroupPlacebo GroupTotal
Hispanic or Latino112
Not Hispanic or Latino6863131
Unknown or Not Reported91524
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vitamin D3 GroupPlacebo GroupTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American424284
White363773
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Vitamin D3 GroupPlacebo GroupTotal
United States7879157
Body Mass Index
Body Mass Index(kilograms/meters^2)Vitamin D3 GroupPlacebo GroupTotal
Mean21.6 ± 5.521.6 ± 6.221.6 ± 5.85
Skin Type
Skin Type(participants)Vitamin D3 GroupPlacebo GroupTotal
I (easy burn, no tan)4610
II (easy burn, slight tan)141327
III (burn, then tan)151631
IV (no burn, good tan)362763
V (never burn, marked tan)71623
Unknown213
Vitamin D-deficient: Defined as serum 25(OH)D <20 ng/mL
Vitamin D-deficient: Defined as serum 25(OH)D <20 ng/mL(participants)Vitamin D3 GroupPlacebo GroupTotal
25(OH)D<20 ng/mL424587
25(OH)D>20 ng/mL363470
08

Study locations

1 site
  • Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15217, United States
09

References and documents

Publications

  • Rajakumar K, Moore CG, Yabes J, Olabopo F, Haralam MA, Comer D, Bogusz J, Nucci A, Sereika S, Dunbar-Jacob J, Holick MF, Greenspan SL. Effect of Vitamin D3 Supplementation in Black and in White Children: A Randomized, Placebo-Controlled Trial. J Clin Endocrinol Metab. 2015 Aug;100(8):3183-92. doi: 10.1210/jc.2015-1643. Epub 2015 Jun 19. PubMed 26091202 ↗
10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 29, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00732758
Lead sponsor
University of Pittsburgh
Responsible party
Kumaravel Rajakumar (Associate Professor of Pediatrics, University of Pittsburgh) — Principal investigator
First posted
Aug 12, 2008
Start date
Oct 2008
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Oct 22, 2015
Last update
Dec 29, 2015

Study contacts

Kumaravel Rajakumar, MD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion